Key Sessions

Arthur Franken

Charting the Course: The 2024 Investment Landscape for European Biotechs

Gilde Healthcare

Susanne Kreutz

Prescription for Success: Navigating the Dynamic World of Pharma M&A in 2024

Novartis

Marta Lesko

Finding the “Golden Egg”: Forging Partnerships that Transform Technologies into Therapeutic Solutions

Merck

Holger Kissel

The Equation for Maturation: Biotech Requirements to Achieve Scale

BioNtech

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

Showing 1 of 1 Streams

BIOTECH LEADERS KEYNOTE PLENARY

09:00 - 09:05

LSX WELCOME ADDRESS

Adam Griffiths - Portfolio Manager, LSX Leaders

09:05 - 09:30

Assessing Biotech Investment Trends in 2024 And Beyond

Cody Powers - Partner, ZS Associates

09:30 - 10:30

Unveiling the Future - The Current Landscape and Spotlighting EU & UK Biotech and Pharma Excellence

Kate Bingham - Managing Partner, SV Health Investors
Sage Revell - Partner, Brown Rudnick
Ryan Richardson - Chief Strategy Officer, BioNTech
Laura Lane - Vice President, Lilly Ventures (Head of Europe), Eli Lilly
Tim Haines - Managing Director, Abingworth
Regina Hodits - Managing Partner, Wellington Partners

Showing 3 of 3 Streams

BIOTECH LEADERS - CAPITAL MARKETS & INVESTMENT

BIOTECH LEADERS - PARTNERSHIPS & DEAL MAKING

BIOTECH LEADERS - SCALING & COMMERCIALISATION

11:10 - 11:50

Charting the Course: The 2024 Investment Landscape for European Biotechs

Arthur Franken - Managing Partner, Gilde Healthcare
Woody Stileman - Managing Director, Strategic Partnerships, RTW Investments
Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners
Claire Brown - Investor, Oxford Science Enterprises
Natasha Barrow - Reporter, Citeline
Vanessa Carle - Senior Associate, Forbion

11:50 - 12:10

Fostering Biotech Innovation - A Perspective From Belgium's Ecosystem

Benoit Kenda - VP and Global Early Solution Partnering, Head, UCB
Amel Tounsi - CEO, Bridge 2 Health
Marc Foidart - CEO, EyED pharma

12:10 - 12:50

Navigating the Investment Frontier: Early-Stage Funding for Biotech Innovators

Daniela Begolo - Managing Director, EQT Life Sciences
Thomas Thestrup - Principal, Angelini Ventures
Clara Campàs Moya - Managing Partner & Cofounder, ASABYS PARTNERS
Sean Kendall - Principal, ARCH Venture Partners
Audrey Warner - Partner, TigerGene LLC
Alex Hamilton - Partner, Syncona

11:10 - 11:50

Striking Your Oncology Deal: New Partnering Approaches & Rethinking Innovation

Duncan Young - Executive Director, Oncology R&D Business Development, AstraZeneca
Sonal Patel - VP, Oncology Scientific Innovation, J&J Innovation
Chris Brown - Senior Director, Oncology BD, GSK
David Jenkins - Senior Vice President, Head of Research & External Innovation, Ipsen
Enda Gribbon - Director, Atelix

11:50 - 12:10

Novartis: Reimagining Medicine through Partnering

Adam Feire - Global Head Search & Evaluation, Corporate & Business Development, Novartis

12:10 - 12:50

Finding the “Golden Egg”: Forging Partnerships that Transform Technologies into Therapeutic Solutions

Marta Lesko - VP, Head of Neurology and Immunology Business Development, Merck
Bernd Nosse - Global Head BD&L Research Beyond Borders & Technologies, Boehringer Ingelheim
Bradley Hardiman - Senior Director, Scouting & Transaction - Business Development, Astellas Pharma Europe
Nerida Scott - Regional Head EMEA, J&J Innovation
Stefano Cottignoli - Head of Corporate Development, Chiesi Group
Ian Johnston - Global Pharmaceutical Correspondant, Financial Times

11:10 - 11:30

Commercial Models Of The Future And How The Biopharma Launch Landscape Is Changing

Ben Hohn - Principal, BD, Pipeline and Launch Strategy, ZS Associates

11:30 - 12:10

Commercial Models Of The Future And How The Biopharma Launch Landscape Is Changing: Expert Panel Discussion

Ben Hohn - Principal, BD, Pipeline and Launch Strategy, ZS Associates
Maria Törnsén - President, North America, Calliditas
John Butler - CEO, Akebia Therapeutics
Vered Bisker-Leib - CEO, Compass Therapeutics

12:10 - 12:50

Expanding Beyond Borders: The Role of BD in Scaling a Global Biotech

Frederic Scaerou - Head of Global Business Development, SERVIER
Sandra von Meier - Head of Business Development & Licensing, Debiopharm
Ragip Ziyal - Head of Coporate Development, Tillotts Pharma
Vishal Sahni - Director, Corporate Business Development & Strategy, H. Lundbeck A/S
Ian Mulvany - CTO, BMJ

Showing 3 of 3 Streams

BIOTECH LEADERS - CAPITAL MARKETS & INVESTMENT

BIOTECH LEADERS - PARTNERSHIPS & DEAL MAKING

BIOTECH LEADERS - SCALING & COMMERCIALISATION

14:00 - 14:40

Accelerating Growth: Investment Strategies for Post Series B Biotech Ventures

Alastair Hugh Lowell Kilgour - Co-Founder & Chief Investment Officer, Parkwalk Advisors
Natalie Torin - Managing Director, Dunhill Ventures
Daniel Parera - Partner, Kurma Partners
Charles Conn - Managing Partner, Monograph Capital
Michael White - Head of Life Sciences, HSBC Innovation Bank, EMEA, HSBC
Alex Hamilton - Partner, Syncona

14:40 - 15:00

Tillotts with a Strong Track Record in Both Partnering and M&A: A Preferred Partner in Europe for Specialty Products

Ragip Ziyal - Head of Coporate Development, Tillotts Pharma

15:00 - 15:40

Public Biotech Playbook: Navigating the Current State of the Markets

Herve Kergrohen - Bioscience Focused Venture Partner, ABO
Max Klement - Principal, Novo Holdings
Ajan Reginald - CEO, Roquefort Therapeutics
John Rudy - Member / Co-chair, Securities & Capital Markets Practice, Mintz
Edouard Guillet - MD, IPF Partners

14:00 - 14:40

Cardiometabolic Disease & Obesity: Unlocking Unique Partnering Opportunities for Biotech

Ashley Zehnder - CEO, Fauna Bio
Alessandro Toniolo - Chief Executive Officer, Resalis Therapeutics
Peng Leong - Chief Business Officer & Head of Brain Aging, BioAge Labs
Steffen-Sebastian Bolz - CSO, Aphaia Pharma
Victoria English - Co-founder and Editor, MedNous

14:40 - 15:00

Debiopharm's Business Model – Developing Innovation Through Investing, Collaboration and Licensing

Sandra von Meier - Head of Business Development & Licensing, Debiopharm

15:00 - 15:40

Advancing CNS Treatments of Tomorrow Through Collaborative Partnerships

Jenny Barnett - CEO, Monument Tx
Jenny Laird - VP Search & Evaluation, Eli Lilly and Company
Kabir Nath - President and CEO, Compass Pathways
Olga Krylova - Head of S&E, Europe, Global Business Development & Innovation, Otsuka
Sahil Kirpekar - CBO, atai Life Sciences

14:00 - 14:40

The Equation for Maturation: Biotech Requirements to Achieve Scale

Holger Kissel - Senior Vice President Scientific Relations and Liaison, BioNtech
Celine Carlet - VP, Head of Transactions, Global BD, Galapagos
Bernd Muehlenweg - SVP Global Business Development, Evotec
Catherine Tucker - VP, Business Development, BenevolentAI

14:40 - 15:00

The Challenges of Scaling up: Learnings from 10 years of Evaluating R&D Productivity

Erika Kuchen - Head of Data-Science, Catenion
Alexander Wallroth - Strategy Consultant, Catenion

15:00 - 15:40

Achieving International Scale Through Accessing Cross Border Opportunities Within the Asia Pacific Market

Donald Xu - Managing Partner, Lynx Capital
Michelle Chen - Chief Business Officer, Insilico Medicine
Astrid Maria Dahl - COO and Head of Innovent Biologics (Europe), Innovent Biologics
Corinne Venot - Executive Director, Business Development, Beigene
James Wang - Head of BD, Adcendo

Showing 1 of 1 Streams

BIOTECH LEADERS AFTERNOON KEYNOTE PLENARY

16:20 - 17:00

The Inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future

Renee Aguiar-Lucander - CEO, Calliditas Therapeutics
Deborah Sterling - Director, Sterne Kessler
Catherine Pickering - CEO, IOnctura
Carlos Buesa - CEO, Oryzon Genomics
Melissa Faris - CBO, OMass Therapeutics

17:00 - 17:40

Prescription for Success: Navigating the Dynamic World of Pharma M&A in 2024

Susanne Kreutz - Global Head, Corporate & Business Development, Novartis
Robbie McLaren - Partner, Latham & Watkins
Chris Sheldon - Senior Vice President, Head of Business Development, GSK
Matthias Müllenbeck - Senior Vice President, Head Global Business Development & Alliance Management, Merck KGaA
Stu Mackey - Global Head Business Development, Daichii-Sankyo
Keld Flintholm Jørgensen - SVP and Chief Business Officer, Lundbeck

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

Get the Latest Event Updates